Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
February 4, 2021

Coronavirus company news summary – GSK and CureVac team up to develop vaccines against emerging Covid-19 variants – Singapore approves Moderna’s vaccine

By Allie Nawrat

4 February 2021

GlaxoSmithKline (GSK) and CureVac have announced a new €150m collaboration, to jointly develop next generation mRNA vaccines against Covid-19. The vaccine will have a multi-valent approach to fight multiple emerging variants. As part of the deal, GSK will also support the development of approximately 100 million doses of CureVac’s Covid-19 vaccine candidate CVnCoV in 2021.

Moderna announced that the Singapore Health Sciences Authority has granted interim authorisation to its mRNA Covid-19 vaccine. The vaccine has been authorised for use through the Pandemic Special Access Route and is based on Phase III results published in November. The Singapore Ministry of Health secured access to Moderna’s vaccine through a supply agreement signed in December 2020.

Bristol Myers Squibb and Rockefeller University signed a definitive agreement, which allows Bristol Myers Squibb to develop, manufacture, as well as commercialise Rockefeller’s new monoclonal antibody duo treatment that neutralises the SARS-CoV-2 virus to treat or prevent Covid-19.

Contract development and manufacturing organisation Avid Bioservices and Humanigen signed a manufacturing services agreement to expand production capacity for Lenzilumab, the latter’s therapeutic candidate for Covid-19. Lenzilumab is a monoclonal antibody that prevents and treats cytokine storm associated with Covid-19. Humanigen completed the enrolment of 520 patients in its Phase III clinical trial of Lenzilumab among hospitalised patients.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy